Morgan Stanley Downgrades Novo Nordisk to Underweight with $40 Target
Sep 11, 2026, 10:27 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A downgrade by a major bank with a price target below the current price often triggers selling pressure and re-pricing expectations, especially when the stock trades above the target. Historical instances show such downgrades leading to 5-15% drawdowns in days to weeks, depending on market sentiment and follow-on commentary.
AI summary
What happened, with direct paths to the underlying reporting
A Morgan Stanley analyst lowered Novo Nordisk to Underweight while keeping a $40 target. With NVO trading around $44.01, the downgrade implies potential near-term underperformance versus the stock’s current price. The note also flags other downgrades (CHWY, SMR, ATO), suggesting broader cautious sentiment among peers and potential volatility for NVO in the near term.
Morgan Stanley downgrades Novo Nordisk to Underweight; PT $40.
NVO closed at $44.01 on Thursday.
Other downgrades in the note: CHWY, SMR, ATO.
Analysts are broadly trimming outlooks; NVO remains near-term risk.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Novo Nordisk announced Wegovy was approved in China for MASH, becoming the first GLP-1 RA cleared for this condition. The approval broadens Wegovy's potential addressable market i…
Novo Nordisk said it halted two additional trials of its experimental cardiovascular drug ziltivekimab, signaling ongoing challenges to expanding beyond obesity and diabetes. The…
Novo Nordisk reported positive late-stage results for Wegovy in children aged 6-11, showing 40.4% no longer obese after 68 weeks with full adherence. The data could broaden Wegovy…
China's drug regulator has accepted Novo Nordisk's oral Wegovy marketing application, a notable regulatory milestone for the obesity drug. If approved, it could broaden Wegovy's C…